Voydeya (Danicopan) Patent Expiration, LOE Window & CMS Spending

Voydeya (Danicopan) by AstraZeneca: FDA Orange Book core substance LOE 2038-03-29 (last listed 2038-08-02), 0 AB generics, $566K 2024 CMS Part D & Medicaid spend, and $5,508 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN218037 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-03-29
Last Listed Patent or Exclusivity Date2038-08-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$566K
2024 Medicare Part D Spend$499K
2024 Medicaid Spend$67K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,508 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.